GlassScriptPhysician profile
Gareth Titus
NPI 1316267750
$2,645.51
in general payments reported to CMS, 2019-2025
26 companies · $483 in 2025
The $483 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $76.54 · 2021: $83.21 · 2022: $405 · 2023: $403 · 2024: $677 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $734.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $241.82 | 2021-2025 | Verquvo |
| Amgen INC. | $226.69 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $218.53 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $206.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $156.47 | 2020-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.78 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $114.36 | 2022-2024 | Brilinta, Wainua |
| Pfizer INC. | $106.92 | 2022-2025 | |
| Esperion Therapeutics, INC. | $76.35 | 2021-2025 | Nexletol |
| Irhythm Technologies, INC. | $74.75 | 2024 | Zio Monitor, Zio Xt Patch |
| Sanofi-Aventis U.S. LLC | $47.63 | 2019-2022 | |
| Novo Nordisk INC | $36.33 | 2025 | Wegovy |
| Boston Scientific Corporation | $36.22 | 2025 | Watchman Flx |
| Philips North America LLC | $35.50 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $34.14 | 2023 | Optimizer |
| Medtronic, INC. | $25.80 | 2021-2023 | Linq II |
| Abbott Laboratories | $21.46 | 2023 | Jot Dx |
| Atricure, INC. | $19.19 | 2024 | |
| Astellas Pharma US INC | $19.13 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.91 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $17.52 | 2023 | Injectafer |
| Cvrx, INC. | $16.38 | 2024 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $14.93 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.39 | 2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gareth Titus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.